<DOC>
	<DOCNO>NCT00460278</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability XL418 subject solid tumor . XL418 new chemical entity inhibit spectrum target , include Akt p70S6K , mediate PI3 Kinase / PTEN signal .</brief_summary>
	<brief_title>Study XL418 Adults With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . The subject histologically confirm solid tumor metastatic unresectable , standard curative palliative measure exist longer effective , know therapy prolong survival . 2 . The subject disease assessable tumor marker , physical , radiologic mean . 3 . The subject ≥18 year old . 4 . The subject 's weight ≥55 kg ≤120 kg . 5 . The subject ECOG ( Eastern Cooperative Oncology Group ) performance status ≤2 . 6 . The subject adequate organ marrow function . 7 . For subject enrol expand MTD cohort : 1. tumor tissue amenable serial biopsy ; 2. additional inform consent . 8 . The subject capable understanding protocol sign informed consent document . 9 . Sexually active subject ( male female ) must use medically acceptable method contraception course study . 10 . Female subject childbearing potential must negative serum pregnancy test screening . 11 . The subject normal fasting blood glucose level screening . 12 . If subject receive three prior regimen cytotoxic chemotherapy , two biological regimen , 3000 cGy area contain substantial marrow , principal investigator ( PI ) sponsor discus subject suitability prior enrollment . 13 . The subject diagnosis malignancy ( unless nonmelanoma skin cancer , situ carcinoma cervix , malignancy diagnose ≥5 year ago , evidence disease 5 year prior screen study ) . 1 . The subject receive anticancer treatment ( eg , chemotherapy , radiotherapy , cytokine , hormone ) within 30 day ( 6 week nitrosoureas mitomycin C ) first dose study drug . 2 . The subject receive radiation ≥25 % bone marrow within 30 day treatment XL418 . 3 . The subject recover either Grade ≤1 adverse event ( AEs ) within 10 % baseline value due investigational agent administer 30 day prior study enrollment . 4 . The subject receive another investigational agent within 30 day first dose study drug . 5 . The subject know brain metastasis . 6 . The subject know diabetes . 7 . The subject uncontrolled intercurrent illness include , limited , ongoing active infection , hypertension , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . 8 . The subject psychiatric illness/social situation would limit compliance study requirement . 9 . The subject pregnant breast feeding . 10 . The subject know positive human immunodeficiency virus ( HIV ) . 11 . The subject know allergy hypersensitivity component XL418 formulation . 12 . The subject baseline QTc interval &gt; 450 ms. 13 . The subject unwilling unable abide study protocol cooperate fully investigator designee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>